A phase I study of AT7519M given twice weekly in patients with advanced incurable malignancy.

Trial Profile

A phase I study of AT7519M given twice weekly in patients with advanced incurable malignancy.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs AT 7519 (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 21 Sep 2011 Planned End Date changed from 1 Oct 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 27 Apr 2011 Actual end date changed from 1 Aug 2009 to 4 Apr 2011 as reported by National Cancer Institute of Canada.
    • 11 Nov 2010 Status changed from recruiting to completed. This trial has recently been completed in 29 patients according to an Astex Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top